



24 April 2018

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call

Brisbane, Australia - ImpediMed Limited (ASX: IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 31 March 2018, on Thursday 26th April 2018.

Investors are invited to join a conference call with Managing Director and CEO, Richard Carreon at **9.00am – 10.00am AEST on Thursday 26th April 2018**.

To pre-register please follow this link:

<https://services.choruscall.com.au/diamondpass/impedimed-380737-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

Media and Investor Contacts:

In Australia:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.